SWOT Analysis for Sarepta Therapeutics Inc

Rising Net Cash Flow and Cash from Operating activity
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Good quarterly growth in the recent results
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Increasing Revenue every quarter for the past 2 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Increasing profits every quarter for the past 2 quarters

PE higher than Industry PE
New 52 week low today
Falling Comet (DVM)
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Highest fall from 52 Week High
Top Losers
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
Near 52 Week Low
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter